Polymyxin-resistant clinical isolates of Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 388-389

  Urban, Carl ^a   Tiruvury, Hemavarna ^a   Mariano, Noriel ^a   Colon Urban, Rita ^c   Rahal, James J ^a,b  

^a NEW YORK HOSPITAL QUEENS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; COTRIMOXAZOLE; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULTAMICILLIN; TIGECYCLINE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CASE REPORT; CELLULITIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; HYDRONEPHROSIS; LABORATORY TEST; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMYXIN B; POLYMYXINS;

EID: 78650660893     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01088-10     Document Type: Article

References (15)

1. Antoniadou, A., F. Kontopidou, G. Poulakou, E. Koratzanis, I. Galani, E. Papadomichelakis, P. Kopterides, M. Souli, A. Armaganides, and H. Giamarellou. 2007. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother. 59:786-790.
2. Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
3. Breazeale, S. D., A. A. Ribeiro, and C. R. H. Raetz. 2003. Origin of lipid A species modified with 4-amino-4-deoxy-L-arabinose in polymyxin-resistant mutants of Escherichia coli. J. Biol. Chem. 278:24731-24739.
4. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors? Nat. Rev. Microbiol. 3:238-250.
5. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Elemam, A., J. Rahimian, and W. Mandell. 2009. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin. Infect. Dis. 49:271-274.
7. Gales, A. C., R. N. Jones, and H. S. Sader. 2006. Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of Gramnegative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect. 12:315-321.
8. Johnson, J. J., B. Johnston, C. Clabots, M. A. Kushowski, and M. Castanheira. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51:286-294.
9. Karisik, E., M. J. Ellington, D. M. Livermore, and N. Woodford. 2008. Virulence factors in Escherichia coli with CTX-M-15 and other extendedspectrum β-lactamases in the UK. J. Antimicrob. Chemother. 61:54-58.
10. Paterson, D. L., and Y. Doi. 2007. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin. Infect. Dis. 45:1179-1181.
11. Rice, L. B. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197:1079-1081.
12. Thiolas, A., C. Bollet, B. La Scola, D. Raoult, and J.-M. Pagés. 2005. Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient. Antimicrob. Agents Chemother. 49:1354-1358.
13. Urban, C., N. Mariano, P. A. Bradford, M. Tuchman, S. Segal-Maurer, W. Wehbeh, L. Grenner, R. Colon-Urban, B. Johnson, J. R. Johnson, and J. J. Rahal. 2010. Identification of CTX-M beta;-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn. Microbiol. Infect. Dis. 66:402-406.
14. Urban, C., P. A. Bradford, M. Tuchman, S. Segal-Maurer, W. Wehbeh, L. Grenner, R. Colon-Urban, N. Mariano, and J. J. Rahal. 2008. Carbapenemresistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin. Infect. Dis. 46:e127-e130.
15. Walkty, A., M. DeCorby, K. Nichol, J. A. Karlowsky, D. J. Hoban, and G. G. Zanel. 2009. In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob. Agents Chemother. 53:4924-4926.